EBS
EBS
US29089Q1058
Emergent BioSolutions Inc.
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 55/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 2.3x as much as the broader market.

Beta (Market Relation)
2.29x
Above average
Volatility (5Y p.a.)
103.7% p.a.
5-Year Horizon
Max Drawdown (5Y)
-97.2%
5-Year Horizon
Sharpe Ratio
-0.35
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -31.1%
3 Years 118.0% -71.2% 0.26 +33.1%
5 Years 103.7% -97.2% -0.35 -33.5%
10 Years 80.6% -98.9% -0.21 -14.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
High market risk: Beta of 2.29 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (118.0%) is noticeably higher than the 5Y average (103.7%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (103.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.9% in the extended horizon.
ende